113 related articles for article (PubMed ID: 30889542)
1. Cathepsin B mediated scramblase activation triggers cytotoxicity and cell cycle arrest by andrographolide to overcome cellular resistance in cisplatin resistant human hepatocellular carcinoma HepG2 cells.
Chowdhury KD; Sarkar A; Chatterjee S; Patra D; Sengupta D; Banerjee S; Chakraborty P; Sadhukhan GC
Environ Toxicol Pharmacol; 2019 May; 68():120-132. PubMed ID: 30889542
[TBL] [Abstract][Full Text] [Related]
2. Synergistic Effect of α-Solanine and Cisplatin Induces Apoptosis and Enhances Cell Cycle Arrest in Human Hepatocellular Carcinoma Cells.
El-Daly SM; Gouhar SA; Gamal-Eldeen AM; Abdel Hamid FF; Ashour MN; Hassan NS
Anticancer Agents Med Chem; 2019; 19(18):2197-2210. PubMed ID: 31566136
[TBL] [Abstract][Full Text] [Related]
3. Cell type-dependent effects of andrographolide on human cancer cell lines.
Cheung MT; Ramalingam R; Lau KK; Chiang WL; Chiu SK
Life Sci; 2012 Oct; 91(15-16):751-760. PubMed ID: 23047020
[No Abstract] [Full Text] [Related]
4. Inhibition of nuclear factor κB transcription activity drives a synergistic effect of cisplatin and oridonin on HepG2 human hepatocellular carcinoma cells.
Dong X; Liu F; Li M
Anticancer Drugs; 2016 Apr; 27(4):286-99. PubMed ID: 26704389
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the JNK signaling pathway increases sensitivity of hepatocellular carcinoma cells to cisplatin by down-regulating expression of P-glycoprotein.
Liu XY; Liu SP; Jiang J; Zhang X; Zhang T
Eur Rev Med Pharmacol Sci; 2016; 20(6):1098-108. PubMed ID: 27049263
[TBL] [Abstract][Full Text] [Related]
6. Minocycline and cisplatin exert synergistic growth suppression on hepatocellular carcinoma by inducing S phase arrest and apoptosis.
Liu FY; Wu YH; Zhou SJ; Deng YL; Zhang ZY; Zhang EL; Huang ZY
Oncol Rep; 2014 Aug; 32(2):835-44. PubMed ID: 24919588
[TBL] [Abstract][Full Text] [Related]
7. SC-III3, a novel scopoletin derivative, induces cytotoxicity in hepatocellular cancer cells through oxidative DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation.
Zhao P; Chen L; Li LH; Wei ZF; Tong B; Jia YG; Kong LY; Xia YF; Dai Y
BMC Cancer; 2014 Dec; 14():987. PubMed ID: 25527123
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of oleanolic acid on hepatocellular carcinoma via ERK-p53-mediated cell cycle arrest and mitochondrial-dependent apoptosis.
Wang X; Bai H; Zhang X; Liu J; Cao P; Liao N; Zhang W; Wang Z; Hai C
Carcinogenesis; 2013 Jun; 34(6):1323-30. PubMed ID: 23404993
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells.
Zhu Q; Yu X; Zhou ZW; Zhou C; Chen XW; Zhou SF
Curr Cancer Drug Targets; 2017; 17(4):386-401. PubMed ID: 27396604
[TBL] [Abstract][Full Text] [Related]
10. A novel all-trans retinoic acid derivative 4-amino‑2‑trifluoromethyl-phenyl retinate inhibits the proliferation of human hepatocellular carcinoma HepG2 cells by inducing G0/G1 cell cycle arrest and apoptosis via upregulation of p53 and ASPP1 and downregulation of iASPP.
Liu H; Chen F; Zhang L; Zhou Q; Gui S; Wang Y
Oncol Rep; 2016 Jul; 36(1):333-41. PubMed ID: 27177208
[TBL] [Abstract][Full Text] [Related]
11. Andrographolide induces cell cycle arrest at G2/M phase and cell death in HepG2 cells via alteration of reactive oxygen species.
Li J; Cheung HY; Zhang Z; Chan GK; Fong WF
Eur J Pharmacol; 2007 Jul; 568(1-3):31-44. PubMed ID: 17512926
[TBL] [Abstract][Full Text] [Related]
12. 2'-epi-2'-O-Acetylthevetin B extracted from seeds of Cerbera manghas L. induces cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells.
Feng B; Guo YW; Huang CG; Li L; Chen RH; Jiao BH
Chem Biol Interact; 2010 Jan; 183(1):142-53. PubMed ID: 19874809
[TBL] [Abstract][Full Text] [Related]
13. NCPMF-60 induces G2/M cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells.
Dai QS; Liu W; Wang XB; Lu N; Gong DD; Kong LY; Guo QL
Anticancer Drugs; 2011 Jan; 22(1):46-57. PubMed ID: 20948430
[TBL] [Abstract][Full Text] [Related]
14. Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1.
Qin J; Luo M; Qian H; Chen W
Gene; 2014 Apr; 538(2):342-7. PubMed ID: 24447717
[TBL] [Abstract][Full Text] [Related]
15. N-Benzoyl-12-nitrodehydroabietylamine-7-one, a novel dehydroabietylamine derivative, induces apoptosis and inhibits proliferation in HepG2 cells.
Lin LY; Bao YL; Chen Y; Sun LG; Yang XG; Liu B; Lin ZX; Zhang YW; Yu CL; Wu Y; Li YX
Chem Biol Interact; 2012 Aug; 199(2):63-73. PubMed ID: 22743618
[TBL] [Abstract][Full Text] [Related]
16. The Ethanolic Extract of Taiwanofungus camphoratus (Antrodia camphorata) Induces Cell Cycle Arrest and Enhances Cytotoxicity of Cisplatin and Doxorubicin on Human Hepatocellular Carcinoma Cells.
Lin LT; Tai CJ; Su CH; Chang FM; Choong CY; Wang CK; Tai CJ
Biomed Res Int; 2015; 2015():415269. PubMed ID: 26557666
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of autophagy by andrographolide resensitizes cisplatin-resistant non-small cell lung carcinoma cells via activation of the Akt/mTOR pathway.
Mi S; Xiang G; Yuwen D; Gao J; Guo W; Wu X; Wu X; Sun Y; Su Y; Shen Y; Xu Q
Toxicol Appl Pharmacol; 2016 Nov; 310():78-86. PubMed ID: 27639426
[TBL] [Abstract][Full Text] [Related]
18. Ursolic acid sensitizes cisplatin-resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway.
Wu S; Zhang T; Du J
Drug Des Devel Ther; 2016; 10():3471-3481. PubMed ID: 27822011
[TBL] [Abstract][Full Text] [Related]
19. A novel anticancer agent, SKLB70359, inhibits human hepatic carcinoma cells proliferation via G0/G1 cell cycle arrest and apoptosis induction.
Dai XY; Zeng XX; Peng F; Han YY; Lin HJ; Xu YZ; Zhou T; Xie G; Deng Y; Mao YQ; Yu LT; Yang L; Zhao YL
Cell Physiol Biochem; 2012; 29(1-2):281-90. PubMed ID: 22415097
[TBL] [Abstract][Full Text] [Related]
20. Allyl-isatin suppresses cell viability, induces cell cycle arrest, and promotes cell apoptosis in hepatocellular carcinoma HepG2 cells.
Bian W; An Y; Qu H; Yang Y; Yang J; Xu Y
Fundam Clin Pharmacol; 2016 Jun; 30(3):253-62. PubMed ID: 26945926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
